Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Peripheral Artery Disease Clinical Trial Pipeline Expands as 17+ Companies Race to Redefine Peripheral Artery Disease Treatment Landscape | DelveInsight

globenewswire.com
CLRS Mentioned as a key company in the Peripheral Artery Disease Market, without any specific performance indicators or future outlook. MDT Mentioned as a key company in the Peripheral Artery Disease and Stenosis Treatment Devices Market and Peripheral Artery Disease Treatment Market, without specific performance details. PHG Listed as a key company in the Peripheral Artery Disease and Stenosis Treatment Devices Market and Peripheral Artery Disease Treatment Market, with no specific performance insights. BSX Mentioned as a key company in the Peripheral Artery Disease and Stenosis Treatment Devices Market and Peripheral Artery Disease Treatment Market, without specific performance details. BDX Listed as a key company in the Peripheral Artery Disease and Stenosis Treatment Devices Market and Peripheral Artery Disease Treatment Market, with no specific performance insights. BIOT Mentioned as a key company in the Peripheral Artery Disease and Stenosis Treatment Devices Market and Peripheral Artery Disease Treatment Market, without specific performance details. ABT Listed as a key company in the Peripheral Artery Disease and Stenosis Treatment Devices Market, Peripheral Artery Disease Treatment Market, and Atherosclerosis Market, with no specific performance insights. ANGI Named as a key company in the Peripheral Artery Disease and Stenosis Treatment Devices Market and Peripheral Artery Disease Treatment Market, but no specific performance data is provided. RMAX Mentioned as a key company in the Peripheral Artery Disease and Stenosis Treatment Devices Market and Peripheral Artery Disease Treatment Market, without specific performance details. MRK Listed as a key company in the Peripheral Artery Disease and Stenosis Treatment Devices Market, Peripheral Artery Disease Treatment Market, and Atherosclerosis Market, with no specific performance insights. SNY Named as a key company in the Peripheral Artery Disease and Stenosis Treatment Devices Market, Peripheral Artery Disease Treatment Market, and Atherosclerosis Market, but no specific performance data is provided. JNJ Mentioned as a key company in the Peripheral Artery Disease and Stenosis Treatment Devices Market and Peripheral Artery Disease Treatment Market, without specific performance details. BA Listed as a key company in the Atherosclerosis Market, with no specific performance insights. GSK Listed as a key company in the Atherosclerosis Market, with no specific performance insights. AZN Mentioned as a key company in the Atherosclerosis Market, without specific performance details. PFE Listed as a key company in the Atherosclerosis Market, with no specific performance insights. NVO Named as a key company in the Atherosclerosis Pipeline Insight, but no specific performance data is provided. AMGN Mentioned as a key company in the Atherosclerosis Pipeline Insight, without specific performance details. VRTX Listed as a key company in the Atherosclerosis Pipeline Insight, with no specific performance insights.

Peripheral Artery Disease Clinical Trial Pipeline Expands as 17+ Companies Race to Redefine Peripheral Artery Disease Treatment Landscape | DelveInsight New York, USA, July 30, 2026 (GLOBE NEWSWIRE) -- Peripheral Artery Disease Clinical Trial Pipeline Expands as 17+ Companies Race to Redefine Peripheral Artery Disease Treatment Landscape | DelveInsight

The peripheral artery disease clinical trial analysis report delivers important insights into ongoing research of 20+ pipeline peripheral artery disease drugs, clinical strategies, upcoming therapeutics, and commercial analysis.

DelveInsight’s 'Peripheral Artery Disease Pipeline Insight 2026' report provides comprehensive global coverage of pipeline therapies for Peripheral Artery Disease across various stages of clinical development. The report offers an in-depth analysis of key trends, emerging therapies, and competitive landscape dynamics, highlighting the strategies of major pharmaceutical companies to advance the pipeline and capitalize on future growth opportunities. In addition, it includes critical insights into clinical trial benchmarking, partnering and licensing activities, and regulatory pathways involving the FDA and EMA, enabling stakeholders to make informed decisions and optimize development strategies within the Peripheral Artery Disease domain.

Peripheral Artery Disease Clinical Trial Analysis Summary

Request a sample and discover the recent advances in peripheral artery disease drug development @ https://www.delveinsight.com/report-store/peripheral-artery-disease-pipeline-insight

What is Peripheral Artery Disease?

Peripheral Artery Disease (PAD) is a common circulatory disorder characterized by the narrowing or blockage of arteries that supply blood to the limbs, most commonly the legs. The condition is primarily caused by atherosclerosis, a process in which fatty deposits accumulate within the arterial walls, reducing blood flow and oxygen delivery to peripheral tissues. Patients with PAD may experience symptoms such as leg pain or cramping during walking, numbness, weakness, slow-healing wounds, and, in severe cases, critical limb ischemia that can lead to tissue loss or amputation. Major risk factors include aging, smoking, diabetes, hypertension, hyperlipidemia, obesity, and a family history of cardiovascular disease. Beyond its impact on limb health, PAD is considered a marker of systemic atherosclerosis and is associated with an increased risk of serious cardiovascular events, including myocardial infarction and stroke. Early diagnosis and management through lifestyle modifications, pharmacological interventions, and, when necessary, revascularization procedures are essential to improve outcomes and reduce disease-related complications.

Find out more about peripheral artery disease drug development @ Peripheral Artery Disease Treatment

A snapshot of the Pipeline Peripheral Artery Disease Drugs mentioned in the report:

Learn more about the emerging peripheral artery disease therapies @ Peripheral Artery Disease Clinical Trials

Peripheral artery disease (PAD) is a progressive vascular disorder in which narrowed or blocked arteries reduce blood flow to the limbs, increasing the risk of cardiovascular and limb-related complications. Rising rates of diabetes, aging populations, and improved diagnosis are expanding the patient pool, driving demand for more effective pharmacological and interventional treatment options.

Recent Developments in the Peripheral Artery Disease Treatment Space

Scope of the Peripheral Artery Disease Pipeline Report

Dive deep into rich insights for new peripheral artery disease treatments, visit @ Peripheral Artery Disease Drugs

Table of Contents

For further information on the peripheral artery disease cure research, reach out @ Medication for Peripheral Artery Disease Treatment

Related Reports

Peripheral Artery Disease Market

Peripheral Artery Disease Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key peripheral artery disease companies, including Ixaka Ltd (formerly Rexgenero), Hemostemix Inc., Lisata Therapeutics, Caladrius Biosciences, Reven Pharmaceuticals, Inc., Helixmith Co., Ltd, and others.

Peripheral Artery Disease And Stenosis Treatment Devices Market

Peripheral Artery Disease And Stenosis Treatment Devices Market Insights, Competitive Landscape, and Market Forecast – 2034 report deliver an in-depth understanding of the market trends, market drivers, market barriers, and key peripheral artery disease and stenosis treatment devices companies, including Medtronic, Koninklijke Philips N.V., B.Braun SE, Boston Scientific Corporation, BD, Terumo Corporation, Biotronik, Cordis, Abbott, AngioDynamics, Cardiovascular Systems, Inc., Bluesail Medical Co., Ltd., Contego Medical, Inc., Argon Medical, Rex Medical, Merck & Co., Inc., Sanofi, Johnson and Johnson Services, Inc., Otivio, Reflow Medical Inc., and others.

Peripheral Artery Disease Treatment Market

Peripheral Artery Disease Treatment Market Insights, Competitive Landscape, and Market Forecast – 2034 report deliver an in-depth understanding of the market trends, market drivers, market barriers, and key peripheral artery disease treatment companies, including Medtronic, Koninklijke Philips N.V., B. Braun SE, Boston Scientific Corporation, BD, Terumo Corporation, Biotronik, Cordis, Abbott, AngioDynamics, Cardiovascular Systems, Inc., Bluesail Medical Co., Ltd., Contego Medical, Inc., Argon Medical, REX Medical, Merck & Co., Inc., Sanofi, Johnson and Johnson Services, Inc., Otivio, Reflow Medical Inc., and others.

Atherosclerosis Market

Atherosclerosis Market Insights, Epidemiology, and Market Forecast – 2036 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key atherosclerosis companies, including Bayer, Janssen, Genentech Inc, BioInvent International AB, GlaxoSmithKline, Merck Sharp & Dohme LLC, Archer Research, Cardionovum GmbH, Sankyo Pharma Gmbh, Daiichi Sankyo Inc, AstraZeneca, Omicron Pharmaceuticals, Abbott, Sanofi, Pfizer, and others.

Atherosclerosis Clinical Trial Analysis

Atherosclerosis Pipeline Insight – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key atherosclerosis companies, including Novo Nordisk, Amgen, Merck Sharp & Dohme, Afimmune, Silence Therapeutics, Verve Therapeutics, 858 Therapeutics, Abionyx Pharma, Bitterroot Bio, and others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.